Alkermes plc. (ALKS): Cost of Revenue
$196.46M
Year ended 2025-12-31
$257.49M
Trailing 12 months to 2026-06-30
-3.4%
3-year compound annual growth
+2.0%
5-year compound annual growth
+3.5%
10-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $196.46M | -19.9% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $245.33M | -3.0% | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | $253.04M | +16.0% | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | $218.07M | +10.5% | 2025-02-12, From 2022-01-01 |
| 2021-12-31 | $197.32M | +10.7% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $178.32M | -1.1% | 2023-02-16, From 2020-01-01 |
| 2019-12-31 | $180.38M | +2.2% | 2022-02-16, From 2019-01-01 |
| 2018-12-31 | $176.42M | +14.0% | 2021-02-11, From 2018-01-01 |
| 2017-12-31 | $154.75M | +17.1% | 2020-02-13, From 2017-01-01 |
| 2016-12-31 | $132.12M | -4.9% | 2019-02-15, From 2016-01-01 |
| 2015-12-31 | $138.99M | -21.0% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $175.83M | n/a | 2017-02-17, From 2014-01-01 |
| No annual figure between 2013-03-31 and 2014-12-31. | |||
| 2013-03-31 | $170.47M | +33.6% | 2015-02-24, From 2012-04-01 |
| 2012-03-31 | $127.58M | +144.5% | 2013-05-23, From 2011-04-01 |
| 2011-03-31 | $52.19M | +5.6% | 2013-05-23, From 2010-04-01 |
| 2010-03-31 | $49.44M | n/a | 2012-05-18, From 2009-04-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Alkermes plc. (ALKS) | 2025-12-31 | $196.46M | -19.9% |
| Phibro Animal Health Corp (PAHC) | 2026-06-30 | $1.01B | +12.2% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $246.00M | +6.5% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $493.13M | -2.0% |
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $89.00M | +8.7% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | $25.50M | n/a |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2024-12-31 | $6.23M | n/a |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
Compare ALKS, PAHC, INDV, PBH side by side · Screen every company in Pharmaceutical Preparations ↗